AR129314A1 - Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1 - Google Patents
Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1Info
- Publication number
- AR129314A1 AR129314A1 ARP230101183A ARP230101183A AR129314A1 AR 129314 A1 AR129314 A1 AR 129314A1 AR P230101183 A ARP230101183 A AR P230101183A AR P230101183 A ARP230101183 A AR P230101183A AR 129314 A1 AR129314 A1 AR 129314A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination therapy
- binding antagonist
- atezolizumab
- administered
- patient
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 3
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title abstract 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 abstract 9
- 229960003852 atezolizumab Drugs 0.000 abstract 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan politerapias que comprenden un inhibidor de SHP2 (por ejemplo, el Compuesto 1) y un antagonista de unión a PD-L1 (por ejemplo, atezolizumab) y procedimientos para usar tales politerapias. Reivindicación 2: La politerapia de la reivindicación 1, en la que el antagonista de unión a PD-L1 es un anticuerpo anti-PD-L1. Reivindicación 3: La politerapia de la reivindicación 1 o 2, en la que el anticuerpo anti-PD-L1 es atezolizumab. Reivindicación 7: La politerapia de una cualquiera de las reivindicaciones 1 a 6, en la que el Compuesto 1 o una sal farmacéuticamente aceptable del mismo, se administra en una cantidad de alrededor de 5 mg - 100 mg. Reivindicación 9: La politerapia de una cualquiera de las reivindicaciones 3 a 8, en la que atezolizumab se administra Q3W en una cantidad de alrededor de 800 mg a alrededor de 1400 mg. Reivindicación 12: La politerapia de una cualquiera de las reivindicaciones 1 a 11, en la que el politerapia se administra a un paciente que la necesita, el paciente tiene cáncer de pulmón, cáncer de cabeza y cuello o melanoma. Reivindicación 17: La politerapia de una cualquiera de las reivindicaciones 12 a 15, en la que el paciente tiene carcinoma de pulmón no microcítico (NSCLC), carcinoma de células escamosas de cabeza y cuello (HNSCC) o melanoma BRAF WT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341361P | 2022-05-12 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129314A1 true AR129314A1 (es) | 2024-08-14 |
Family
ID=86710772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101183A AR129314A1 (es) | 2022-05-12 | 2023-05-12 | Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1 |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR129314A1 (es) |
| TW (1) | TW202408523A (es) |
| WO (1) | WO2023220703A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
| EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| AU2010324757C1 (en) | 2009-11-24 | 2018-05-17 | Medimmune Limited | Targeted binding agents against B7-H1 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| KR102284247B1 (ko) | 2012-05-31 | 2021-08-03 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| JP7048319B2 (ja) | 2015-05-12 | 2022-04-05 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| AU2016270625B2 (en) | 2015-05-29 | 2022-10-06 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| US20220127271A1 (en) * | 2018-11-07 | 2022-04-28 | Shanghai Ringene Biopharma Co., Ltd. | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use |
| CN114450287A (zh) * | 2019-09-24 | 2022-05-06 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其制备和使用方法 |
-
2023
- 2023-05-12 AR ARP230101183A patent/AR129314A1/es unknown
- 2023-05-12 WO PCT/US2023/066920 patent/WO2023220703A1/en unknown
- 2023-05-12 TW TW112117719A patent/TW202408523A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202408523A (zh) | 2024-03-01 |
| WO2023220703A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goedegebuure et al. | Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer? | |
| Wachowska et al. | 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy | |
| Watanabe | Current chemotherapeutic approaches for hepatoblastoma | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| Numico et al. | Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| Nasr et al. | ST 1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model | |
| Shi et al. | Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation | |
| BR112023023463A2 (pt) | Inibidores da interação menin-mll | |
| Keller et al. | Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment | |
| WO2020141828A3 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
| AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma | |
| AR129314A1 (es) | Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1 | |
| Colquhoun et al. | Combination treatment with ionising radiation and gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo | |
| Yan et al. | Novel applications for an established antimalarial drug: Tumoricidal activity of quinacrine | |
| KR20200050761A (ko) | 다이설피람을 포함하는 항암용 조성물 | |
| US10952975B2 (en) | Compositions and methods for treatment of cancer | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente |